MedPath

Tolerance of Cereals for Atopic Children

Not Applicable
Terminated
Conditions
Allergy
Interventions
Other: commercialized complete cereals
Other: commercialized complete cereals with additional ingredient
Registration Number
NCT01029184
Lead Sponsor
Société des Produits Nestlé (SPN)
Brief Summary

In this study, non allergenic cereals will be tested in infants with atopic symptoms. The test will be performed in a hospital.

Detailed Description

In the majority of food allergy cases, an exclusion diet results in regression of clinical symptoms but this diet may not be nutritionally complete. To feed a baby who has a food allergy, we want a food with low allergenic ingredients.

For this reason, a complete cereal has been specially developed and formulated for the weaning period of infants and young children suffering from milk, soy or wheat protein allergy or hypersensitivity due to celiac disease.

It allows a smooth transition into and through the weaning period. The ingredients of this product are all from vegetable sources and it is therefore suitable for a vegetarian diet. It has been commercialised for many years and has proved to be completely safe, however so far no study has been specifically designed and powered to assess tolerance of this product in infants with atopic symptoms.

In this study we are testing the tolerance (symptoms stability) of non allergenic cereals during an open allergenic test in infants with atopic symptoms and/or positive Skin Prick Test (SPT) or positive specific RAST-IgE or positive Patch Test. We are also testing the same product containing an additional ingredient with a potential effect in allergy management.

Such complete cereals is a very good option for allergic children in comparison to an exclusion diet that may not be nutritionally complete.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
45
Inclusion Criteria
  • Infant aged from 4 to 40 months at the time of enrolment
  • With atopic symptoms and/or positive Skin Prick Test (SPT) or positive specific RAST-IgE or positive Patch Test
  • Infants who received a specific elimination oligoallergenic diet from the study site for at least 5 days before the day of enrolment
  • Having obtained his/her signed legal representative's informed consent
Exclusion Criteria
  • Infant on systemic drugs (e.g. antihistamines) according to half-life at time of enrolment
  • Congenital illness or malformation that may affect normal growth (especially immunodeficiency)
  • Infant whose parents / caregivers cannot be expected to comply with treatment.
  • Infant currently participating in another interventional clinical trial

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
complete non allergenic cerealscommercialized complete cerealsexisting commercialized product
complete non allergenic cereals pluscommercialized complete cereals with additional ingredientcommercialised product with the addition of a novel ingredient
Primary Outcome Measures
NameTimeMethod
Documentation of atopic symptoms and clinical examination for presence or absence of some objective and subjective symptoms with evaluation of severity (SCORAD) if necessary48 hours
Secondary Outcome Measures
NameTimeMethod
Morbidity will be assessed by the frequency of adverse events48 hours

Trial Locations

Locations (1)

Kinderarzt-Allergologie-Sportmedizin Fachklinik Gaißach

🇩🇪

Gaißach bei Bad Tölz, Germany

© Copyright 2025. All Rights Reserved by MedPath